Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Ackermans & van Haaren verhoogt haar belang in Van Moer Logistics tot 40%

GlobeNewswire

Geachte aandeelhouder,

Geachte mevrouw, geachte heer,

Ackermans & van Haaren heeft via haar 100%-dochter AvH Growth Capital een overeenkomst gesloten om haar belang in Van Moer Logistics tot 39,77% te verhogen.

Van Moer Logistics is een geïntegreerde logistieke dienstverlener die actief is op het gebied van multimodaal transport, haven- en binnenvaartlogistiek, warehousing, logistiek met toegevoegde waarde, expeditie en onsite logistiek.

Gelieve bijgevoegd ons persbericht te vinden.

Met vriendelijke groeten,

Ackermans & van Haaren

  1. Share Buy-back Programme – Transactions Week 42On 12 May 2026, Gabriel Holding A/S initiated a share buy-back programme. The buy-back runs from 12 May 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital.
  2. Aktietilbagekøbsprogram – transaktioner uge 42Den 12. maj 2026 igangsatte Gabriel Holding A/S et aktietilbagekøbsprogram. Aktietilbagekøbet løber i perioden fra og med den 12. maj til og med den 16. marts 2027. I denne periode kan Gabriel Holding A/S tilbagekøbe op til en samlet beholdning på 94.500 egne aktier svarende til 5 % af aktiekapitalen.
  3. FinanceEgide - Half-year results at June 30, 2026: Net loss more than halved, amounting to €0.87m, Net financial debt reduced to €4.99mEgide Group reported a consolidated net loss of -€0.87m, compared with -€2.04m in the first half of 2025, and consolidated revenue of €15.20m.
  4. TelecomTPAYtpay Selected as Vodafone Qatar’s Direct Operator Billing AggregatorCompanies: VodafoneLong-standing partnership expands as tpay becomes Vodafone Qatar’s Direct Operator Billing aggregator, building on a proven track record of major digital service launches
  5. HealthcareOculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye DiseaseHigh-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials
  6. OSB GROUP PLC - Transaction in Own SharesOSB GROUP PLC ISIN: GB00BLDRH360 19 October 2026